Insulin-associated neuroinflammatory pathways as therapeutic targets for traumatic brain injury

Medical Hypotheses

Volumn 82, Issue 2, 2014, Pages 171-174

  Cerecedo López, Christian D ^a,b   Kim Lee, Jennifer H ^a,b   Hernandez, Diana ^b   Acosta, Sandra A ^b   Borlongan, Cesar V ^b  

^a UNIVERSIDAD ANÁHUAC   (Mexico)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; GLUCOSE; INSULIN; SCAVENGER RECEPTOR;

ARTICLE; BRAIN DAMAGE; CELL DEATH; CELL DIFFERENTIATION; CELL TYPE; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTHESIS; NERVOUS SYSTEM INFLAMMATION; TRAUMATIC BRAIN INJURY;

ANTIGENS, CD36; BLOOD GLUCOSE; BRAIN INJURIES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; INFLAMMATION; INSULIN; LIPOPROTEINS, LDL; MODELS, THEORETICAL; NEURONS; UNITED STATES;

EID: 84892371082     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.11.028     Document Type: Article

References (62)

1. Faul M., Xu L., Wald M.M., Coronado V.G. Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002-2006 2010, Centers for Disease Control and Prevention; National Center for Injury Prevention and Control, Atlanta, GA.
2. Corrigan J.D., Selassie A.W., Orman J.A. The epidemiology of traumatic brain injury. J Head Trauma Rehabil 2010, 25(2).
3. Bhattacharjee Y. Neuroscience Shell shock revisited: solving the puzzle of blast trauma. Science 2008 Jan 25, 319(5862):406-408.
4. Gubata ME, Packnett ER, Blandford CD, Piccirillo AL, Niebuhr DW, Cowan DN. Trends in the Epidemiology of Disability Related to Traumatic Brain Injury in the US Army and Marine Corps: 2005 to 2010. J Head Trauma Rehabil 9000;Publish Ahead of Print.
5. Puvanachandra P., Hyder A.A. Traumatic brain injury in Latin America and the Caribbean: a call for research. Salud Publica Mex 2008, 50:s3-s5.
6. Werner C., Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007 Jul, 99(1):4-9.
7. Doyle K.P., Buckwalter M.S. The double-edged sword of inflammation after stroke: what sharpens each edge?. Ann Neurol 2012, 71(6):729-731.
8. Luo X., Chen S. The changing phenotype of microglia from homeostasis to disease. Transl Neurodegeneration 2012, 1(1):9.
9. Koshinaga M., Katayama Y., Fukushima M., Oshima H., Suma T., Takahata T. Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices. J Neurotrauma 2000 Mar, 17(3):185-192.
10. Bachstetter A.D., Rowe R.K., Kaneko M., Goulding D., Lifshitz J., Van Eldik L.J. The p38alpha MAPK regulates microglial responsiveness to diffuse traumatic brain injury. J Neurosci 2013 Apr 3, 33(14):6143-6153.
11. Finnie J.W. Neuroinflammation: beneficial and detrimental effects after traumatic brain injury. Inflammopharmacology 2013 Aug, 21(4):309-320.
12. Laird M.D., Shields J.S., Sukumari-Ramesh S., Kimbler D.E., David Fessler R., Shakir B. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia 2013 Oct 28.
13. Zhang Z., Zhang Z.Y., Wu Y., Schlusener H.J. Immunolocalization of Toll-like receptors 2 and 4 as well as their endogenous ligand, heat shock protein 70, in rat traumatic brain injury. Neuroimmunomodulation 2012, 19(1):10-19.
14. Tandon N.N., Lipsky R.H., Burgess W.H., Jamieson G.A. Isolation and characterization of platelet glycoprotein IV (CD36). J Biol Chem 1989 May 05, 264(13):7570-7575.
15. Collot-Teixeira S., Martin J., McDermott-Roe C., Poston R., McGregor J.L. CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007 August 01, 75(3):468-477.
16. Tran T.T.T., Poirier H., Clément L., Nassir F., Pelsers M.M.A.L., Petit V., et al. Luminal lipid regulates CD36 levels and downstream signaling to stimulate chylomicron synthesis. J Biol Chem 2011 July 15, 286(28):25201-25210.
17. Goldberg I.J., Eckel R.H., Abumrad N.A. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res 2009 April 01, 50(Supplement):S86-S90.
18. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010 Feb, 11(2):155-161.
19. Navazo M.D.P., Daviet L., Ninio E., McGregor J.L. Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL). Arterioscler Thromb Vasc Biol 1996 August 01, 16(8):1033-1039.
20. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003 Jun, 9(6):736-743.
21. Vale A.M., Kapoor P., Skibinski G.A., Elgavish A., Mahmoud T.I., Zemlin C., et al. The link between antibodies to OxLDL and natural protection against pneumococci depends on D(H) gene conservation. J Exp Med 2013 May 6, 210(5):875-890.
22. Smith A., John B. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(Suppl. 1):s5-s10.
23. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States 2011, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
24. Hernández-Ávila M., Gutiérrez J.P. Diabetes mellitus: la urgencia de reforzar la respuesta en políticas públicas para su prevención y control ́ 2012, Instituto Nacional de Salud Publica, Mexico, [cited 2013 Nov 9]. http://ensanut.insp.mx/doctos/analiticos/DiabetesMellitus.pdf.
25. Diabetes in Canada: facts and figures from a public health perspective 2011, Public Health Agency of Canada, Public Health Agency of Canada, Ottawa.
26. Yoshida H., Kisugi R. Mechanisms of LDL oxidation. Clinica Chimica Acta 2010 12/14, 411(23-24):1875-1882.
27. Kaplan M., Aviram M., Hayek T. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy. Pharmacol Ther 2012 Nov, 136(2):175-185.
28. Green K., Brand M.D., Murphy M.P. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004 February 01, 53(Suppl. 1):S110-S118.
29. 2+ and ROS. Front Biosci 2009 Jan, 1(14):1197-1218.
30. Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B., Carpenter S.B., et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 2013 06/30, 23:10-12. [advance online publication].
31. Cho S., Kim E. CD36: a multi-modal target for acute stroke therapy. J Neurochem 2009 May, 109(Suppl. 1):126-132.
32. Snipelisky D., Ziajka P. Diabetes and hyperlipidemia: a direct quantitative analysis-a direct analysis of the effects of insulin resistance on lipid levels in relation to atherosclerotic coronary artery disease. World J Cardiovasc Dis 2012, 2(1):20-25.
33. Werner C., Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007 July 01, 99(1):4-9.
34. Santos M.S., Moreno A.J., Carvalho A.P. Relationships between ATP depletion, membrane potential, and the release of neurotransmitters in rat nerve terminals: an In vitro study under conditions that mimic anoxia, hypoglycemia, and ischemia. Stroke 1996 May 01, 27(5):941-950.
35. Korde A.S., Pettigrew L.C., Craddock S.D., Maragos W.F. The mitochondrial uncoupler 2,4-dinitrophenol attenuates tissue damage and improves mitochondrial homeostasis following transient focal cerebral ischemia. J Neurochem 2005, 94(6):1676-1684.
36. Pandya J.D., Pauly J.R., Nukala V.N., Sebastian A.H., Day K.M., Korde A.S., et al. Post-injury administration of mitochondrial uncouplers increases tissue sparing and improves behavioral outcome following traumatic brain injury in rodents. J Neurotrauma 2007 May, 24(5):798-811.
37. Sorce S., Krause K.H. NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal 2009 Oct, 11(10):2481-2504.
38. Chen H., Yoshioka H., Kim G.S., Jung J.E., Okami N., Sakata H., et al. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal 2011 Apr 15, 14(8):1505-1517.
39. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990 Feb, 87(4):1620-1624.
40. Yurdakan G., Tekin I.O., Comert M., Acikgoz S., Sipahi E.Y. The presence of oxidized low-density lipoprotein and inducible nitric oxide synthase expression in renal damage after intestinal ischemia reperfusion. Kaohsiung J Med Sci 2012 Jan, 28(1):16-22.
41. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011, 34(1):185-204.
42. 2 production: major link between oxidative stress and BACE1. Neurotox Res 2012 10/01, 22(3):208-219.
43. Moore K.J., Freeman M.W. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006 August 01, 26(8):1702-1711.
44. Silverstein R.L., Li W., Park Y.M., Rahaman S.O. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans Am Clin Climatol Assoc 2010, 121:206-220.
45. Rahaman S.O., Lennon D.J., Febbraio M., Podrez E.A., Hazen S.L., Silverstein R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 2006 Sep, 4(3):211-221.
46. Grebe A., Latz E. Cholesterol crystals and inflammation. Curr Rheumatol Rep 2013 Mar, 15(3):313. 012-0313-z.
47. Freigang S., Ampenberger F., Spohn G., Heer S., Shamshiev A.T., Kisielow J., et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 2011 Jul, 41(7):2040-2051.
48. Kouadir M., Yang L., Tan R., Shi F., Lu Y., Zhang S., et al. CD36 Participates in PrP 106-126 Induced Activation of Microglia. PLoS One 2012 01/26, 7(1):e30756.
49. Coraci I.S., Husemann J., Berman J.W., Hulette C., Dufour J.H., Campanella G.K., et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to β-Amyloid fibrils. Am J Pathol 2002, 160(1):101-112.
50. El Khoury J.B., Moore K.J., Means T.K., Leung J., Terada K., Toft M., et al. CD36 mediates the innate host response to β-Amyloid. J Exp Med 2003 June 16, 197(12):1657-1666.
51. Moore K.J., El Khoury J., Medeiros L.A., Terada K., Geula C., Luster A.D., et al. A CD36-initiated signaling cascade mediates inflammatory effects of β-Amyloid. J Biol Chem 2002 December 06, 277(49):47373-47379.
52. Ley E.J., Srour M.K., Clond M.A., Barnajian M., Tillou A., Mirocha J., et al. Diabetic patients with traumatic brain injury: insulin deficiency is associated with increased mortality. J Trauma 2011 May, 70(5):1141-1144.
53. Yoshino A., Hovda D.A., Kawamata T., Katayama Y., Becker D.P. Dynamic changes in local cerebral glucose utilization following cerebral concussions in rats: evidence of a hyper- and subsequent hypometabolic state. Brain Res 1991 Oct 4, 561(1):106-119.
54. Hemphill J.C., Andrews P., De Georgia M. Multimodal monitoring and neurocritical care bioinformatics. Nat Rev Neurol 2011 Jul 12, 7(8):451-460.
55. Van den B., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M. Intensive insulin therapy in critically Ill patients. N Engl J Med 2001, 345(19):1359-1367.
56. Campdelacreu J. Parkinson disease and Alzheimer disease: environmental risk factors. Neurologia 2012 Jun 13.
57. Lee P.C., Bordelon Y., Bronstein J., Ritz B. Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology 2012 Nov 13, 79(20):2061-2066.
58. Weykamp C. HbA1c: a review of analytical and clinical aspects. Ann Lab Med 2013 Nov, 33(6):393-400.
59. Kim E., Tolhurst A.T., Qin L.Y., Chen X.Y., Febbraio M., Cho S. CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. J Neurosci 2008 Apr 30, 28(18):4661-4670.
60. Green D.M., O'Phelan K.H., Bassin S.L., Chang C.W., Stern T.S., Asai S.M. Intensive versus conventional insulin therapy in critically ill neurologic patients. Neurocrit Care 2010 Dec, 13(3):299-306.
61. Rachmany L., Tweedie D., Li Y., Rubovitch V., Holloway H., Miller J., et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age 2012, 08(15):1-16.
62. Wang J., Gallagher D., DeVito L.M., Cancino G.I., Tsui D., He L., et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012 Jul 6, 11(1):23-35.